HUMA חוב כולל להון Humacyte

Humacyte, Inc. (HUMA) operates a state-of-the-art artificial tissue production complex in North Carolina featuring independent power supply and strict temperature control. The organization collaborates with hospitals and military medicine to implement innovative vessels for injury rehabilitation. This price chart on GURU.Markets shows that the debt-to-equity ratio is 2.27, while the business relies on in-house tissue production and delegates the procurement of consumables to trusted suppliers.

This ratio compares total liabilities to equity, determining the business's degree of reliance on borrowed funds. During periods of volatility, it serves as a stress-testing tool for the issuer's solvency. Analyzing the business's leverage ratio allows for a rapid assessment of bankruptcy risk or expansion potential. For Humacyte, Inc. (HUMA), low indebtedness complements the stability of its sovereign product cycle. Stable demand for biomedical innovations makes the company a reliable defensive asset.